Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
Kalendit removes the middleman (agencies) and provides UK nurseries with temporary staff while helping them save up to 50% on staffing fees. Since September, over 150 users joined Kalendit, and it is continuing to add about two workers daily. This company had launched its services in November with four nurseries, and since then, have been successfully processed 49 bookings. With the funds raised, it will hire people and serve thirty nurseries in one year. By the fifth year, it wants to take 45% of the London market, which equates to 1400 nurseries.
days to go:
Expired
investment:
£82,180
MyFirstUK is a car insurance platform for first time driver. It aims to offer young people the perfect cover at the right price and also provide them with all of the guidance they need to make an informed decision.
days to go:
Expired
investment:
£61,920
For Good Causes turn Loyalty points into donations for charities, giving people a new way to give to causes closest to their hearts. Brands are given a while new CSR opportunity and charities are given much-needed funding. Research has shown their is over £7bn unused rewards in the UK, values which could be donated.
days to go:
Expired
investment:
£292,220
Actve is on a mission to change the way people connect with their favourite fitness creators. The company aspires to help creators earn an income and build a subscription business. Actve asserts that it caters to a variety of creator needs allowing them to live-stream their workouts, offer guided programs to customers, or use Actve's software to manage their clients. The company aims to become a contender in the digital fitness market that is projected to be worth £21 billion by 2022. It aims to launch its platform in September 2021. Actve will use the investment to develop its platform, hire key staff, build its user base, and work towards becoming an industry champion for fitness creators.
days to go:
Expired
investment:
£165,627
Charm is a peer-to-peer impact investment platform that allows a user to use his/her investments to drive positive change in the world while earning a financial return. Morgan Stanley estimates that 85% of people are interested in sustainable investing. Charm enables individuals to fund projects led by high-impact entrepreneurs selling clean energy solutions in developing economies. Users can view their investments on the company's transparent, personalised impact investment dashboard, as well as, earn social, environmental and financial bottom line returns for their contributions. The company secured a £496,000 grant funding to develop its platform, refine its offering & provide growth capital. It is in the process of becoming an appointed representative of a Financial Conduct Authority (FCA) authorised entity post this funding round. It will use the investment to expand its team, develop its platform, and raise brand awareness.
days to go:
Expired
investment:
£273,720
Docandu is an innovative digital health platform designed both for patients & doctors, making digital healthcare accessible from anywhere. Docandu aims to be a key tech health service provider, starting from Greece, improving the existing national and private health care services. The global digital health market is estimated to be worth $536 Billion by 2025. To date, they have developed two separate apps for doctors and patients. They have also received an angel investment of 100,000 Euros and sponsorship of $25,000 from Microsoft. The company has initiated early-stage relationships with a couple of Greek public and private health entities. With the proceeds, they will execute their go-to-market strategy and make global health ID a reality, by expanding its affiliate network of doctors, health providers and public health systems.
days to go:
Expired
investment:
£70,900
